Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002751 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody Therapy in Treating Patients With Brain Metastases
A Phase 1 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00002751 is a Phase 1 study that has completed, run by Duke University. The registered enrollment target is 6 participants.
The verdict
NCT00002751, a Phase 1 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have brain metastases.
Interventions
- BIOLOGICAL monoclonal antibody Me1-14 F(ab')2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 1989-07 |
| Est. Completion | 2004-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002751
The ClinicalTrials.gov registry entry for NCT00002751 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which monoclonal antibody Me1-14 F(ab')2 is the first listed.
NCT00002751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002751 about?
NCT00002751 is a clinical study titled "Monoclonal Antibody Therapy in Treating Patients With Brain Metastases". RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have brain metastases.
What is the current status of trial NCT00002751?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 1989-07. Estimated completion is 2004-05.
What interventions are being tested in trial NCT00002751?
The interventions under investigation include: monoclonal antibody Me1-14 F(ab')2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002751?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.